Raphael Pharmaceutical annual r&d spending
2020
2021
2022
2023
2024
2025
Raphael Pharmaceutical R&D Spending Growth & History (RAPH)
Raphael Pharmaceutical's r&d spending was $631,000 for fiscal 2025.
View full Raphael Pharmaceutical company overviewRaphael Pharmaceutical annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $631,000 | −$145,000 | −18.69% |
| 2024 | 2024-12-31 | $776,000 | $207,000 | +36.38% |
| 2023 | 2023-12-31 | $569,000 | −$609,000 | −51.70% |
| 2022 | 2022-12-31 | $1.2M | $402,000 | +51.80% |
| 2021 | 2021-12-31 | $776,000 | $315,000 | +68.33% |
| 2020 | 2020-12-31 | $461,000 | — | — |
Raphael Pharmaceutical quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $40,000 | −$101,000 | −71.63% |
| Q1 2026 | 2026-03-31 | $37,000 | −$35,000 | −48.61% |
| Q4 2025 | 2025-12-31 | $345,000 | $134,000 | +63.51% |
| Q3 2025 | 2025-09-30 | $73,000 | −$89,000 | −54.94% |
| Q2 2025 | 2025-06-30 | $141,000 | $117,000 | +487.50% |
| Q1 2025 | 2025-03-31 | $72,000 | −$307,000 | −81.00% |
| Q4 2024 | 2024-12-31 | $211,000 | — | — |
| Q3 2024 | 2024-09-30 | $162,000 | −$348,000 | −68.24% |
| Q2 2024 | 2024-06-30 | $24,000 | −$269,000 | −91.81% |
| Q1 2024 | 2024-03-31 | $379,000 | $265,000 | +232.46% |
| Q3 2023 | 2023-09-30 | $510,000 | $178,000 | +53.61% |
| Q2 2023 | 2023-06-30 | $293,000 | $209,000 | +248.81% |
| Q1 2023 | 2023-03-31 | $114,000 | $28,000 | +32.56% |
| Q4 2022 | 2022-12-31 | $676,000 | $452,000 | +201.79% |
| Q3 2022 | 2022-09-30 | $332,000 | $171,000 | +106.21% |
| Q2 2022 | 2022-06-30 | $84,000 | −$138,000 | −62.16% |
| Q1 2022 | 2022-03-31 | $86,000 | −$83,000 | −49.11% |
| Q4 2021 | 2021-12-31 | $224,000 | — | — |
| Q3 2021 | 2021-09-30 | $161,000 | $92,000 | +133.33% |
| Q2 2021 | 2021-06-30 | $222,000 | — | — |
| Q1 2021 | 2021-03-31 | $169,000 | — | — |
| Q3 2020 | 2020-09-30 | $69,000 | — | — |
Raphael Pharmaceutical r&d spending trends
Over the last five fiscal years, Raphael Pharmaceutical's r&d spending increased from $461,000 to $631,000, a change of $170,000. The latest reported quarter, Q2 2026, shows $40,000.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Raphael Pharmaceutical source filings ↗